# AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

> **NCT02284906** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 40 (actual)

## Conditions studied

- Mild Cognitive Impairment Due to Alzheimer's Disease

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02284906
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-12
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-05-08
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Lack of efficacy of the drug; no safety concern
- **Last updated:** 2019-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02284906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02284906, "AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02284906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*